Introducing Ragistomig and Its Role in Cancer Treatment
Ragistomig, a unique bispecific antibody combining 4-1BB X PD-L1, aims to change the landscape for patients who face relapsed or refractory conditions, particularly after battling through the common checkpoint inhibitors that many cancer drugs rely on. The challenges posed by resistance in this multi-billion dollar industry have prompted the team at NovaBridge to innovate and provide more effective options.
Exciting Phase 1 Study Results
Recently, NovaBridge Biosciences (Nasdaq: NBP), a forward-thinking biotechnology company, announced strong results from its Phase 1 study of Ragistomig. The trial achieved significant milestones by introducing a new dosing strategy at intervals of every six weeks (Q6W). This adjustment not only demonstrated robust anti-tumor efficacy in patients who did not respond to previous PD-L1 therapies but also showcased an enhanced safety profile.
Dr. Phillip Dennis, the Chief Medical Officer of NovaBridge, highlighted the results by stating that this new dosing schedule enhances the drug's therapeutic window, balancing efficacy with a better tolerability profile, especially concerning liver safety. These positive findings pave the way for subsequent combination studies that could revolutionize patient care.
Presentation at ESMO-IO
The comprehensive interim results will be unveiled at the prestigious European Society for Medical Oncology – Immuno-Oncology Congress 2025 (ESMO-IO 2025), scheduled for December. Leading the presentation will be Dr. Gerald Falchook from the Sarah Cannon Research Institute, who will discuss the immunological data, including CD8+ cell proliferation and memory T-cell activation.
ESMO-IO Presentation Highlights
The key details for the presentation include:
- Title: Phase 1 Clinical Trial of Ragistomig (ABL503/TJ-L14B: PD-L1 × 4-1BB bispecific antibody) Q6W Dosing Balances Favorable Safety and Sustained Efficacy Through Extended Immunologic Memory and Reinvigoration of CD8+ T Cells
- Abstract: #688
- Date and Time: A session on December 10, 2025, at 5:30 PM GMT
Understanding the Mechanism of Ragistomig
Ragistomig is designed to integrate effectively in the battle against tumors by specifically targeting PD-L1, while also activating T cells selectively in the presence of PD-L1 expressing tumor cells. This innovative design, stemming from ABL Bio’s “Grabody-T” platform technology, significantly reduces the risk of off-tumor toxicity, a common concern with many cancer therapies. Previous preclinical studies have shown that Ragistomig outperforms its individual components in terms of anti-tumor activity.
About NovaBridge Biosciences
NovaBridge stands out as a global biotechnology company dedicated to accelerating access to breakthrough medicines. Their approach combines expertise in business development with agile clinical development, which facilitates the swift transition of transformative therapies from discovery to patient applications. Currently leading their pipeline are givastomig, a bispecific antibody targeting Claudin 18.2 x 4-1BB, and VIS-101, aimed at improving treatment for conditions like wet age-related macular degeneration.
Ongoing Research and Development
NovaBridge continues to explore the potential of Ragistomig in various solid tumors, especially those resistant to current treatments. Alongside their partner ABL Bio, they are optimistic about the ongoing progress in clinical trials aimed at expanding the therapeutic options for patients battling cancer.
Frequently Asked Questions
What is Ragistomig?
Ragistomig is a bispecific antibody designed to target cancer cells resistant to standard checkpoint inhibitors, combining PD-L1 and 4-1BB to enhance immune response.
When will the results of the Phase 1 study be presented?
The results will be showcased on December 10, 2025, during a session at ESMO-IO 2025.
What are the benefits of the Q6W dosing schedule?
The Q6W dosing schedule facilitates robust anti-tumor efficacy while maintaining a favorable safety profile, allowing for potentially improved patient outcomes.
How does NovaBridge contribute to cancer treatment?
NovaBridge accelerates the development of innovative medicines designed to enhance treatment options for patients suffering from various forms of cancer.
What other products are in NovaBridge's pipeline?
Key products in their pipeline include givastomig, targeting Claudin 18.2, and VIS-101 for retinal conditions, alongside the development of Ragistomig.
